No Data
No Data
Jiangsu Hengrui Medicine Gets Approval for Clinical Trial of Heart Failure Injection
Jiangsu Hengrui Pharmaceuticals (600276.SH): The resubmission of the biological product application for Injection Caririzumab Monoclonal Antibody has been accepted by the FDA.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received a notice from the Food and Drug Administration (FDA) in the United States...
Jiangsu Hengrui Pharmaceuticals (600276.SH): HR19042 capsules included in the list of breakthrough treatment varieties.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced on October 14th that its HR19042 capsules have been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration Drug Evaluation Center (referred to as the "Drug Evaluation Center"). Intended indication (or main function): used for the treatment of active autoimmune hepatitis.
Jiangsu Hengrui Medicine Gets Marketing Authorization for T-cell Lymphoma Tablets
Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR2554 tablet's market approval application has been accepted.
Geelonghui October 13th | Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received the "Acceptance Notice" issued by the National Medical Products Administration. The company's SHR2554 tablet's pharmaceutical market approval application has been accepted by the National Medical Products Administration and has been included in the list of varieties for priority review. Proposed indications (or main functions): used for relapsed or refractory peripheral T-cell lymphoma that has previously received at least 1st line systemic treatment.
US FDA Approves Hengrui Medicine's Abbreviated New Drug Application for Anti-Cancer Injection
No Data
No Data